Actively Recruiting
National Longitudinal Cohort of Hematological Diseases (NICHE) - CART
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-06-17
1000
Participants Needed
1
Research Sites
604 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, ambispective, longitudinal, observational cohort study investigating CAR-T cell therapy in Chinese patients with hematological malignancies. A consortium of Phase IV clinical trials and real-world studies of Chimeric antigen receptors (CAR) T cell therapy will be established in China. Patient-level data from these studies will be collected to create a large real-world cohort. In addition, patients receiving CAR-T cell therapy for hematological malignancies identified from an existing hematology longitudinal cohort study, the National Longitudinal Cohort of Hematological Diseases (NICHE), will also be included in the study.
CONDITIONS
Official Title
National Longitudinal Cohort of Hematological Diseases (NICHE) - CART
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with clinically diagnosed hematologic malignancies
- Patients treated with CAR-T cell therapy
- Signed the informed consent form
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China, 300000
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here